Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model

被引:33
作者
Baishanbo, A
Gargala, G
Duclos, C
François, A
Rossignol, JF
Ballet, JJ
Favennec, L
机构
[1] CHU Charles Nicolle, Parasitol Lab, ADEN, F-76031 Rouen, France
[2] Xinjiang Med Univ, Coll Pharm, Urumqi, Peoples R China
[3] CHU Clemenceau, Immunol Lab, F-14033 Caen, France
[4] CHU Charles Nicolle, Serv Anat Pathol, F-76031 Rouen, France
[5] Romark Inst Med Res, Tampa, FL 33607 USA
关键词
Cryptosporidium parvum; Meriones unguiculatus; gall bladders; cryptosporidial cholangitis;
D O I
10.1093/jac/dki456
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
Objectives: To evaluate the efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed Mongolian gerbil (Meriones unguiculatus) model. Methods: Gerbils (1-month-old) were dexamethasone-immunosuppressed for 10 days and challenged orally with 10(5) Cryptosporidium parvum oocysts. From day 0 to day 12 post-infection, one group (n = 14) was treated with 200 mg/kg/day nitazoxanide and another (n = 15) with 100 mg/kg/day paromomycin. Infection and efficacy of nitazoxanide and paromomycin were assessed by measuring oocyst shedding in faeces, biliary tract and ileum histological examination. Results: In nitazoxanide-treated and paromomycin-treated groups as compared with untreated animals (P < 0.05), oocyst shedding was partially suppressed in a similar manner (P > 0.05). Parasites were present in histological sections of the ileal mucosa of 16/16 infected untreated animals versus 3/14 and 6/15 in the nitazoxanide-treated and the paromomycin-treated groups, respectively (P < 0.05). In addition, gall bladder infection was less frequent in nitazoxanide-treated (2/14, P < 0.01) and paromomycin-treated (5/15, P = 0.07) animals than in untreated controls (9/16). No histological alteration of biliary mucosa was observed in both treated and untreated infected gerbils. Conclusions: Present data support the efficacy of nitazoxanide and, to a lesser extent, paromomycin on biliary C. parvum infection in gerbils, and prompt further investigation of the potential clinical benefits of nitazoxanide in treating human biliary cryptosporidiosis.
引用
收藏
页码:353 / 355
页数:3
相关论文
共 17 条
[1]
Infectivity of Cryptosporidium hominis and Cryptosporidium parvum genotype 2 isolates in immunosuppressed Mongolian gerbils [J].
Baishanbo, A ;
Gargala, G ;
Delaunay, A ;
François, A ;
Ballet, JJ ;
Favennec, L .
INFECTION AND IMMUNITY, 2005, 73 (08) :5252-5255
[2]
Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model [J].
Blagburn, BL ;
Drain, KL ;
Land, TM ;
Kinard, RG ;
Moore, PH ;
Lindsay, DS ;
Patrick, DA ;
Boykin, DW ;
Tidwell, RR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2877-2882
[3]
Broekhuysen J, 2000, INT J CLIN PHARM TH, V38, P387
[4]
Cryptosporidiosis and the pathogenesis of AIDS-cholangiopathy [J].
Chen, XM ;
LaRusso, NF .
SEMINARS IN LIVER DISEASE, 2002, 22 (03) :277-289
[5]
NATURAL-HISTORY OF AIDS RELATED SCLEROSING CHOLANGITIS - A STUDY OF 20 CASES [J].
FORBES, A ;
BLANSHARD, C ;
GAZZARD, B .
GUT, 1993, 34 (01) :116-121
[6]
Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells [J].
Gargala, G ;
Delaunay, A ;
Li, XD ;
Brasseur, P ;
Favennec, L ;
Ballet, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (01) :57-60
[7]
Cryptosporidiosis of the gastrointestinal tract associated with sclerosing cholangitis in the absence of documented immunodeficiency:: Cryptosporidium parvum and sclerosing cholangitis in an immunocompetent child [J].
Goddard, EA ;
Mouton, SCE ;
Westwood, ATR ;
Ireland, JD ;
Durra, G .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2000, 31 (03) :317-320
[8]
Hayward AR, 1997, J IMMUNOL, V158, P977
[9]
Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients [J].
Hunter, PR ;
Nichols, G .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (01) :145-+
[10]
Ko WF, 2003, AM J GASTROENTEROL, V98, P2176, DOI [10.1016/S0002-9270(03)00751-2, 10.1111/j.1572-0241.2003.07718.x]